Site Details
LOCATION
E3 Building, Hanoi Medical University
No. 1 Ton That Tung Street
Dong Da District Hanoi,
Hanoi , 10000
SiteType
CRS
Site Trials
Treatment Experienced
Active, Not Recruiting
ACTG A5402: An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons with HIV: COPE
A5402 is a phase II, open-label, randomized clinical trial comparing the efficacy and safety of two medications (pramipexole versus escitalopram) for treating major depressive disorder (MDD), including with mild neurocognitive disorder (MND), in persons with HIV (PWH) over 24 weeks. The study will also look at any effect on activities of daily living.
Treatment Experienced
A5385: An Observational Post-Intervention Cohort Destination Protocol
This study is a two-step, non-interventional extension study for individuals participating in another interventional HIV cure trial (parent study) that includes an analytical treatment interruption (ATI) (stopping anti-HIV therapy [ART] while monitoring viral load). Participants will be individuals who achieved post-intervention control (PIC) (maintaining HIV suppression after treatment interruption) in their parent study.
Step 1 will consist of an extended ATI period in which PICs will be monitored for safety, viral, and immune outcomes. Time to viral rebound and restart of antiretroviral therapy (ART) will be measured. Participants will begin Step 2 if they meet ART restart criteria and will be monitored for safety, immune, and viral outcomes through 48 weeks after ART restart.